Meeting
2019 ASCO Annual Meeting
Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.
Authors
Miguel J. Gil Gil
Breast Cancer Unit & Medical Oncology Department, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain
Miguel J. Gil Gil , Francisco Javier Perez , Teresa Soler Monso , Tomas Pascual , Patricia Galván , Laia Pare , Anna Petit , Catalina Falo , Agostina Stradella , María Jesús Pla , Ramon Salazar , Aleix Prat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 575)
DOI
10.1200/JCO.2019.37.15_suppl.575
Abstract #
575
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).
First Author: Jennifer Bordeaux
Poster
2022 ASCO Annual Meeting
Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.
First Author: Felix Blanc-Durand
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2024 ASCO Genitourinary Cancers Symposium
The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.
First Author: Zilin Wang